You need JavaScript to view this

FDG-PET in monitoring therapy of breast cancer

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88-91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer. (orig.)
Authors:
Biersack, H J; Bender, H; Palmedo, H [1] 
  1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn (Germany)
Publication Date:
Jun 01, 2004
Product Type:
Journal Article
Resource Relation:
Journal Name: European Journal of Nuclear Medicine and Molecular Imaging; Journal Volume: 31; Journal Issue: 1,Suppl.; Other Information: PBD: Jun 2004
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; PATIENTS; DIAGNOSIS; RADIOPHARMACEUTICALS; ACCURACY; MAMMARY GLANDS; CARCINOMAS; REVIEWS; FLUORINE 18; FLUORODEOXYGLUCOSE; POSITRON COMPUTED TOMOGRAPHY; CHEMOTHERAPY; EFFICIENCY
OSTI ID:
20502039
Country of Origin:
Germany
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 1619-7070; TRN: DE04F8771
Availability:
Available from: http://dx.doi.org/10.1007/s00259-004-1533-x
Submitting Site:
DEN
Size:
page(s) S112-S117
Announcement Date:
Sep 23, 2004

Citation Formats

Biersack, H J, Bender, H, and Palmedo, H. FDG-PET in monitoring therapy of breast cancer. Germany: N. p., 2004. Web. doi:10.1007/s00259-004-1533-x.
Biersack, H J, Bender, H, & Palmedo, H. FDG-PET in monitoring therapy of breast cancer. Germany. doi:10.1007/s00259-004-1533-x.
Biersack, H J, Bender, H, and Palmedo, H. 2004. "FDG-PET in monitoring therapy of breast cancer." Germany. doi:10.1007/s00259-004-1533-x. https://www.osti.gov/servlets/purl/10.1007/s00259-004-1533-x.
@misc{etde_20502039,
title = {FDG-PET in monitoring therapy of breast cancer}
author = {Biersack, H J, Bender, H, and Palmedo, H}
abstractNote = {Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been used successfully for the staging and re-staging of breast cancer. Another significant indication is the evaluation of therapy response. Only limited data are available on the use of FDG-PET in breast cancer after radiation therapy. The same holds true for chemotherapy. Only the therapy response in locally advanced breast cancer after chemotherapy has been investigated thoroughly. Histopathological response could be predicted with an accuracy of 88-91% after the first and second courses of therapy. A quantitative evaluation is, of course, a prerequisite when FDG-PET is used for therapy monitoring. Only a small number of studies have focussed on hormone therapy. In this context, a flare phenomenon with increasing standardised uptake values after initiation of tamoxifen therapy has been observed. More prospective multicentre trials will be needed to make FDG-PET a powerful tool in monitoring chemotherapy in breast cancer. (orig.)}
doi = {10.1007/s00259-004-1533-x}
journal = {European Journal of Nuclear Medicine and Molecular Imaging}
issue = {1,Suppl.}
volume = {31}
journal type = {AC}
place = {Germany}
year = {2004}
month = {Jun}
}